Alembic Pharmaceuticals has informed that their Associate Company, Rhizen Pharmaceuticals S.A. (Rhizen) has released a Press Release announcing that the USFDA has granted Orphan-Drug Designation for Tenalisib (RP6530). Couple of weeks back also the company had informed that USFDA has granted Fast Track Designation for Tenalisib (RP6530) to Rhizen.
The above information is a part of company’s filings submitted to BSE.